Myelin Regeneration in Multiple Sclerosis: Targeting Endogenous Stem Cells

Neurotherapeutics

Volumn 8, Issue 4, 2011, Pages 650-658

  Huang, Jeffrey K ^a   Fancy, Stephen P J ^b   Zhao, Chao ^a   Rowitch, David H ^b   ffrench Constant, Charles ^c   Franklin, Robin J M ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Multiple sclerosis; Regenerative medicine; Remyelination; Stem cell

Indexed keywords

HYALURONIC ACID; MYELIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; NOTCH RECEPTOR; SEMAPHORIN; THYROID HORMONE RECEPTOR; WNT PROTEIN;

CELL ADHESION; CELL REGENERATION; HUMAN; MULTIPLE SCLEROSIS; NERVE FIBER DEGENERATION; NERVE FIBER GROWTH; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; CENTRAL NERVOUS SYSTEM; HUMANS; MULTIPLE SCLEROSIS; MYELIN SHEATH; NERVE REGENERATION; STEM CELLS;

EID: 81155131911     PISSN: 19337213     EISSN: 18787479     Source Type: Journal    
DOI: 10.1007/s13311-011-0065-x     Document Type: Review

References (88)

1. Compston A, Coles A. Multiple sclerosis. Lancet 2008; 372: 1502-1517.
2. Martino G, Franklin RJM, Baron van Evercooren A, Kerr D, Group SC. Stem cell transplantation in multiple sclerosis: current status and future prospects. Nat Rev Neurol 2010; 6: 247-255.
3. Franklin RJM, ffrench-Constant C. Stem cell treatments and multiple sclerosis. BMJ 2010; 340: 986-985.
4. Trapp BD, Nave KA. Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci 2008; 31: 247-269.
5. Waxman SG. Axonal conduction and injury in multiple sclerosis: the role of sodium channels. Nat Rev Neurosci 2006; 7: 932-941.
6. Oksenberg JR, Baranzini SE, Sawcer S, Hauser SL. The genetics of multiple sclerosis: SNPs to pathways to pathogenesis. Nat Rev Genet 2008; 9: 516-526.
7. Coles AJ, Compston DA, Selmaj KW, et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 2008; 359: 1786-1801.
8. Nave KA, Trapp BD. Axon-glial signaling and the glial support of axon function. Annu Rev Neurosci 2008; 31: 535-561.
9. Nave KA. Myelination and the trophic support of long axons. Nat Rev Neurosci 2010; 11: 275-283.
10. Coles AJ, Wing MG, Molyneux P, et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol 1999; 46: 296-304.
11. Dutta R, Trapp BD. Pathogenesis of axonal and neuronal damage in multiple sclerosis. Neurology 2007; 68(22 suppl 3): S22-S31.
12. Lappe-Siefke C, Goebbels S, Gravel M, et al. Disruption of Cnp1 uncouples oligodendroglial functions in axonal support and myelination. Nat Genet 2003; 33: 366-374.
13. Griffiths I, Klugmann M, Anderson T, et al. Axonal swellings and degeneration in mice lacking the major proteolipid of myelin. Science 1998; 280: 1610-1613.
14. Li C, Tropak MB, Gerlal R, et al. Myelination in the absense of myelin-associated glycoprotein. Nature 1994; 369: 747-750.
15. Pohl HB, Porcheri C, Mueggler T, et al. Genetically induced adult oligodendrocyte cell death is associated with poor myelin clearance, reduced remyelination, and axonal damage. J Neurosci 2011; 31: 1069-1080.
16. Edgar JM, Nave KA. The role of CNS glia in preserving axon function. Curr Opin Neurobiol 2009; 5: 498-504.
17. Irvine KA, Blakemore WF. Remyelination protects axons from demyelination-associated axon degeneration. Brain 2008; 131: 1464-1477.
18. Liebetanz D, Merkler D. Effects of commissural de- and remyelination on motor skill behaviour in the cuprizone mouse model of multiple sclerosis. Exp Neurol 2006; 202: 217-224.
19. Jeffery ND, Crang AJ, O'Leary MT, Hodge SJ, Blakemore WF. Behavioural consequences of oligodendrocyte progenitor cell transplantation into demyelinating lesions in rat spinal cord. Eur J Neurosci 1999; 11: 1508-1514.
20. Smith KJ, Blakemore WF, McDonald WI. Central remyelination restores secure conduction. Nature 1979; 280: 395-396.
21. Duncan ID, Brower A, Kondo Y, Curlee JF Jr, Schultz RD. Extensive remyelination of the CNS leads to functional recovery. Proc Natl Acad Sci U S A 2009; 106: 6832-6836.
22. Rivers LE, Young KM, Rizzi M, et al. PDGFRA/NG2 glia generate myelinating oligodendrocytes and piriform projection neurons in adult mice. Nat Neurosci 2008; 11: 1392-1401.
23. Nunes MC, Roy NS, Keyoung HM, et al. Identification and isolation of multipotential neural progenitor cells from the subcortical white matter of the adult human brain. Nat Med 2003; 9: 439-247.
24. Zhu X, Bergles DE, Nishiyama A. NG2 cells generate both oligodendrocytes and gray matter astrocytes. Development 2008; 135: 145-157.
25. Tripathi RB, Rivers LE, Young KM, Jamen F, Richardson WD. NG2 glia generate new oligodendrocytes but few astrocytes in a murine experimental autoimmune encephalomyelitis model of demyelinating disease. J Neurosci 2010; 30: 16383-16390.
26. Glezer I, Lapointe A, Rivest S. Innate immunity triggers oligodendrocyte progenitor reactivity and confines damages to brain injuries. FASEB J 2006; 20: 750-752.
27. Watanabe M, Hadzic T, Nishiyama A (2004) Transient upregulation of Nkx2. 2 expression in oligodendrocyte lineage cells during remyelination. Glia 46: 311-322.
28. Zhao C, Fancy SPJ, Franklin RJM, ffrench-Constant C. Upregulation of oligodendrocyte precursor cell αv integrin and its extracellular ligands during CNS remyelination. J Neurosci Res 2009; 87: 3447-3455.
29. Fancy SPJ, Zhao C, Franklin RJM. Increased expression of Nkx2. 2 and Olig2 identifies reactive oligodendrocyte progenitor cells responding to demyelination in the adult CNS. Mol Cell Neurosci 2004; 27: 247-254.
30. Crockett DP, Burshteyn M, Garcia C, Muggironi M, Casaccia-Bonnefil P. Number of oligodendrocyte progenitors recruited to the lesioned spinal cord is modulated by the levels of the cell cycle regulatory protein p27Kip-1. Glia 2005; 49: 301-308.
31. Chen Y, Wu H, Wang S, et al. The oligodendrocyte-specific G protein-coupled receptor GPR17 is a cell-intrinsic timer of myelination. Nat Neurosci 2009; 12: 1398-406.
32. Woodruff RH, Fruttiger M, Richardson WD, Franklin RJM. Platelet-derived growth factor regulates oligodendrocyte progenitor numbers in adult CNS and their response following CNS demyelination. Mol Cell Neurosci 2004; 25: 252-262.
33. Sim FJ, Zhao C, Penderis J, Franklin RJM. The age-related decrease in CNS remyelination efficiency is attributable to an impairment of both oligodendrocyte progenitor recruitment and differentiation. J Neurosci 2002; 22: 2451-2459.
34. Shields SA, Gilson JM, Blakemore WF, Franklin RJM. Remyelination occurs as extensively but more slowly in old rats compared to young rats following gliotoxin-induced CNS demyelination. Glia 1999; 28: 77-83.
35. Shen S, Sandoval J, Swiss V, et al. Age-dependent epigenetic control of differentiation inhibitors: a critical determinant of remyelination efficiency. Nat Neurosci 2008; 11: 1024-1034.
36. Kuhlmann T, Miron V, Cuo Q, Wegner C, Antel J, Bruck W. Differentiation block of oligodendroglial progenitor cells as a cause for remyelination failure in chronic multiple sclerosis. Brain 2008; 131: 1749-58.
37. Chang A, Tourtellotte WW, Rudick R, Trapp BD. Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis. N Engl J Med 2002; 346: 165-173.
38. Wolswijk G. Chronic stage multiple sclerosis lesions contain a relatively quiescent population of oligodendrocyte precursor cells. J Neurosci 1998; 18: 601-609.
39. Scolding N, Franklin R, Stevens S, Heldin CH, Compston A, Newcombe J. Oligodendrocyte progenitors are present in the normal adult human CNS and in the lesions of multiple sclerosis. Brain 1998; 121: 2221-2228.
40. Gilson J, Blakemore WF. Failure of remyelination in areas of demyelination produced in the spinal cord of old rats. Neuropathol Appl Neurobiol 1993; 19: 173-181.
41. Zhao C, Li WW, Franklin RJM. Differences in the early inflammatory responses to toxin-induced demyelination are associated with the age-related decline in CNS remyelination. Neurobiol Aging 2006; 27; 1298-1307.
42. Robinson S, Miller RH. Contact with central nervous system myelin inhibits oligodendrocyte progenitor maturation. Dev Biol 1999; 216: 359-368.
43. Kotter MR, Li WW, Zhao C, Franklin RJM. Myelin impairs CNS remyelination by inhibiting oligodendrocyte precursor cell differentiation. J Neurosci 2006; 26: 328-232.
44. Baer AS, Syed YA, Kang SU, et al. Myelin-mediated inhibition of oligodendrocyte precursor differentiation can be overcome by pharmacological modulation of Fyn-RhoA and protein kinase C signalling. Brain 2009; 132: 465-481.
45. Back SA, Tuohy TM, Chen H, et al. Hyaluronan accumulates in demyelinated lesions and inhibits oligodendrocyte progenitor maturation. Nat Med 2005; 11: 966-972.
46. Sloane JA, Batt C, Ma Y, Harris ZM, Trapp B, Vartanian T. Hyaluronan blocks oligodendrocyte progenitor maturation and remyelination through TLR2. Proc Natl Acad Sci U S A 2010; 107: 11555-11560.
47. Williams A, Piaton G, Aigrot MS, et al. Semaphorin 3A and 3F: key players in myelin repair in multiple sclerosis? Brain 2007; 130: 2554-2565.
48. Piaton G, Aigrot MS, Williams A, et al. Class 3 semaphorins influence oligodendrocyte precursor recruitment and remyelination in adult central nervous system. Brain 2011; 134: 1156-1167.
49. Syed YA, Hand E, Mobius W, et al. Inhibition of CNS Remyelination by the Presence of Semaphorin 3A. J Neurosci 2011; 31: 3719-3728.
50. Charles P, Reynolds R, Seilhean D, et al. Re-expression of PSA-NCAM by demyelinated axons: an inhibitor or remyelination in multiple sclerosis? Brain 2002; 125: 1972-1979.
51. Mi S, Lee X, Shao Z, et al. LINGO-1 is a component of the Nogo-66 receptor/p75 signaling complex. Nat Neurosci 2004; 7: 221-228.
52. Mi S, Miller RH, Lee X, et al. LINGO-1 negatively regulates myelination by oligodendrocytes. Nat Neurosci 2005; 8: 745-751.
53. Mi S, Hu B, Hahm K, et al. LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitis. Nat Med 2007; 13: 1228-1233.
54. Mi S, Miller RH, Tang W, et al. Promotion of central nervous system remyelination by induced differentiation of oligodendrocyte precursor cells. Ann Neurol 2009; 65: 304-315.
55. Fancy SPJ, Baranzini SE, Zhao C, et al. Dysregulation of the Wnt pathway inhibits timely myelination and remyelination in the mammalian CNS. Genes Dev 2009; 23: 1571-1585.
56. Ye F, Chen Y, Hoang T, et al. HDAC1 and HDAC2 regulate oligodendrocyte differentiation by disrupting the beta-catenin-TCF interaction. Nat Neurosci 2009; 12: 829-838.
57. Fu H, Cai J, Clevers H, et al. A genome-wide screen for spatially restricted expression patterns identifies transcription factors that regulate glial development. J Neurosci 2009; 29: 11399-11408.
58. Nelson WJ, Nusse R. Convergence of Wnt, beta-catenin, and cadherin pathways. Science 2004; 303: 1483-1487.
59. Barker N, Clevers H. Mining the Wnt pathway for cancer therapeutics. Nat Rev Drug Discov 2006; 5: 997-1014.
60. Franklin RJM, Crang AJ, Blakemore WF. The role of astrocytes in the remyelination of glia-free areas of demyelination. Adv Neurol 1993; 59: 125-33.
61. Williams A, Piaton G, Lubetzki C. Astrocytes - friends or foes in multiple sclerosis? Glia 2007; 55: 1300-1312.
62. John GR, Shankar SL, Shafit-Zagardo B, et al. Multiple sclerosis: Re-expression of a developmental pathway that restricts oligodendrocyte maturation. Nat Med 2002; 8: 1115-1121.
63. Stidworthy MF, Genoud S, Li WW, et al. Notch1 and Jagged1 are expressed after CNS demyelination but are not a major rate-determining factor during remyelination. Brain 2004; 127; 1928-1941.
64. Seifert T, Bauer J, Weissert R, Fazekas F, Storch MK (2006) Notch1 and its ligand Jagged1 are present in remyelination in a T-cell- and antibody-mediated model of inflammatory demyelination. Acta Neuropathol(Berl) 113: 195-203.
65. Zhang Y, Argaw AT, Gurfein BT, et al. Notch1 signaling plays a role in regulating precursor differentiation during CNS remyelination. Proc Natl Acad Sci U S A 2009; 106: 19162-19167.
66. Jurynczyk M, Jurewicz A, Bielecki B, Raine CS, Selmaj K. Inhibition of Notch signaling enhances tissue repair in an animal model of multiple sclerosis. J Neuroimmunol 2005; 170: 3-10.
67. Hoyne GF, Dallman MJ, Champion BR, Lamb JR. Notch signalling in the regulation of peripheral immunity. Immunol Rev 2001; 182: 215-227.
68. Hu QD, Ang BT, Karsak M, et al. F3/Contactin acts as a functional ligand for notch during oligodendrocyte maturation. Cell 2003; 115: 163-175.
69. Nakahara J, Kanekura K, Nawa M, Aiso S, Suzuki N. Abnormal expression of TIP30 and arrested nucleocytoplasmic transport within oligodendrocyte precursor cells in multiple sclerosis. J Clin Invest 2009; 119: 169-181.
70. Germain P, Chambon P, Eichele G, et al. International Union of Pharmacology. LXIII. Retinoid X receptors. Pharmacol Rev 2006; 58: 760-772.
71. Lefebvre P, Benomar Y, Staels B. Retinoid X receptors: common heterodimerization partners with distinct functions. Trends Endocrinol Metab 2010; 21: 676-683.
72. Schrage K, Koopmans G, Joosten EA, Mey J. Macrophages and neurons are targets of retinoic acid signaling after spinal cord contusion injury. Eur J Neurosci 2006; 23: 285-295.
73. Saluja I, Granneman JG, Skoff RP. PPAR delta agonists stimulate oligodendrocyte differentiation in tissue culture. Glia 2001; 33: 191-204.
74. Wang L, Schuster GU, Hultenby K, Zhang Q, Andersson S, Gustafsson JA. Liver X receptors in the central nervous system: from lipid homeostasis to neuronal degeneration. Proc Natl Acad Sci U S A 2002; 99: 13878-13883.
75. Altucci L, Leibowitz MD, Ogilvie KM, de Lera AR, Gronemeyer H. RAR and RXR modulation in cancer and metabolic disease. Nat Rev Drug Discov 2007; 6: 793-810.
76. Xu J, Drew PD. 9-Cis-retinoic acid suppresses inflammatory responses of microglia and astrocytes. J Neuroimmunol 2006; 171: 135-144.
77. Baranzini SE, Wang J, Gibson RA, et al. Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. Hum Mol Genet 2009; 18: 767-778.
78. Lock C, Hermans G, Pedotti R, et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med 2002; 8: 500-508.
79. Han MH, Hwang SI, Roy DB, et al. Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets. Nature 2008; 451: 1076-1081.
80. van Es JH, Clevers H. Notch and Wnt inhibitors as potential new drugs for intestinal neoplastic disease. Trends Mol Med 2005; 11: 496-502.
81. Takahashi-Yanaga F, Sasaguri T. The Wnt/beta-catenin signaling pathway as a target in drug discovery. J Pharmacol Sci 2007; 104: 293-302.
82. Huang SM, Mishina YM, Liu S, et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 2009; 461: 614-620.
83. Ballanger F, Nguyen JM, Khammari A, Dreno B. Evolution of clinical and molecular responses to bexarotene treatment in cutaneous T-cell lymphoma. Dermatology 2010; 220: 370-375.
84. Diab A, Hussain RZ, Lovett-Racke AE, Chavis JA, Drew PD, Racke MK. Ligands for the peroxisome proliferator-activated receptor-gamma and the retinoid X receptor exert additive anti-inflammatory effects on experimental autoimmune encephalomyelitis. J Neuroimmunol 2004; 148: 116-126.
85. Lecca D, Trincavelli ML, Gelosa P, et al. The recently identified P2Y-like receptor GPR17 is a sensor of brain damage and a new target for brain repair. PLoS One 2008; 3: e3579.
86. Pasquini LA, Paez PM, Moreno MA, Pasquini JM, Soto EF. Inhibition of the proteasome by lactacystin enhances oligodendroglial cell differentiation. J Neurosci 2003; 23: 4635-4644.
87. Gadea A, Aguirre A, Haydar TF, Gallo V. Endothelin-1 regulates oligodendrocyte development. J Neurosci 2009; 29: 10047-10062.
88. Sabo JK, Aumann TD, Merlo D, Kilpatrick TJ, Cate HS. Remyelination is altered by bone morphogenic protein signaling in demyelinated lesions. J Neurosci 2011; 31: 4504-4510.